Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Moodys
Johnson and Johnson
Colorcon
Merck

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Nepadutant

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Nepadutant: Patents, clinical trial progress, indications

Nepadutant is an investigational drug.

There have been 4 clinical trials for Nepadutant. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2011.

The most common disease conditions in clinical trials are Colic, Gastrointestinal Diseases, and Digestive System Diseases. The leading clinical trial sponsors are Menarini Group and [disabled in preview].

There are five US patents protecting this investigational drug and two hundred and one international patents.

Recent Clinical Trials for Nepadutant
TitleSponsorPhase
Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding IntoleranceMenarini GroupPhase 2
Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant With Colic Not Responding to Conventional TreatmentMenarini GroupPhase 2
Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant ColicMenarini GroupPhase 2

See all Nepadutant clinical trials

Clinical Trial Summary for Nepadutant

Top disease conditions for Nepadutant
Top clinical trial sponsors for Nepadutant

See all Nepadutant clinical trials

US Patents for Nepadutant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Nepadutant   Start Trial Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists Boehringer Ingelheim Pharma KG (Ingelheim, DE)   Start Trial
Nepadutant   Start Trial Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists Boehringer Ingelheim Pharma KG (Ingelheim, DE)   Start Trial
Nepadutant   Start Trial Pharmaceutical aerosol composition Pari GmbH (Starnberg, DE)   Start Trial
Nepadutant   Start Trial Surface topographies for non-toxic bioadhesion control University of Florida Research Foundation, Inc. (Gainesville, FL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Nepadutant

Drugname Country Document Number Estimated Expiration Related US Patent
Nepadutant Argentina 034213 2021-03-07   Start Trial
Nepadutant Argentina 038494 2021-03-07   Start Trial
Nepadutant Argentina 038765 2020-10-31   Start Trial
Nepadutant Austria 430581 2020-10-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Merck
Mallinckrodt
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.